Patent Application
20090197919
The present invention relates to a process for synthesis of salts of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (esomeprazole), in a pure and isolated form.
The compound 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole, having the generic name omeprazole, and therapeutically acceptable salts thereof, are described in EP 0 005 129.
Omeprazole is a sulfoxide and a chiral compound, wherein the sulphur atom being the stereogenic center. Thus, omeprazole is a racemic mixture of its two single enantiomers, the R- and S-enantiomer of omeprazole, herein referred to as R-omeprazole and S-omeprazole, the latter have the generic name esomeprazole. The absolute configuration of the enantiomers of omeprazole has been determined by an X-ray study of an N-alkylated derivate of the R-enantiomer.
Omeprazole and esomeprazole are proton pump inhibitors, and are useful as antiulcer agents. In a more general sense, omeprazole and esomeprazole may be used for prevention and treatment of gastric acid related diseases in mammals and especially in man. Specific alkaline salts of omeprazole are disclosed in EP 0 124 495. Herein, quaternary ammonium salts and guanidine salts of omeprazole are disclosed. Document WO 97/41114 discloses processes for preparing magnesium salt of benzimidazoles, including magnesium salt of omeprazole.
Certain salts of the single enantiomers of omeprazole and their preparation are disclosed in WO 94/27988, for instance, quaternary ammonium salts of esomeprazole are mentioned. The described salts of esomeprazole have improved pharmacokinetic and metabolic properties, which will give an improved therapeutic profile such as a lower degree of interindividual variation. WO 96/02535 and WO 98/54171 disclose preferred processes for preparing esomeprazole and salts thereof.
In the formulation of drug compositions, it is important for the active pharmaceutical ingredient to be in a form in which it can be conveniently handled and processed. This is of importance, not only from the point of view of obtaining a commercially viable manufacturing process, but also from the point of view of subsequent manufacture of pharmaceutical formulations (e.g. oral dosage forms such as tablets) comprising the active pharmaceutical ingredient.
Further, in the manufacture of oral pharmaceutical compositions, it is important that a reliable, reproducible and constant plasma concentration profile of the active pharmaceutical ingredient is provided following administration to a patient.
Chemical stability, solid state stability, and “shelf life” of the active pharmaceutical ingredient are important properties for a pharmaceutical active compound. The active pharmaceutical ingredient, and compositions containing it, should be capable of being effectively stored over appreciable periods of time, without exhibiting a significant change in the physico-chemical characteristics of the active pharmaceutical ingredient, e.g. its chemical composition, density, hygroscopicity and solubility.
The present invention refers to a process for preparing a quartenary ammonium salt of esomeprazole of formula I
wherein
R1, R2, R3 and R4 are individually selected from
(A) C1-C14 alkyl group, which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O—, C3-C12 cycloalkyl (which cycloalkyl is optionally substituted by one or more groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, oxo, R23aOC(O)—, (R23b)(R23c)NC(O)—, R23dC(O)N(R23e)—, R23fC(O)O—, R23gOC(O)—NH—, (R23h)(R23j)NC(O)O—), aryl or Het1 (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, —CH2OH, halogen, oxo, nitro, C1-C7 alkoxy, R24aOC(O)—, (R24b)(R24c)NC(O)—, R24dC(O)N(R24e)—, R24fC(O)O—, R24gOC(O)—NH—, (R24h)(R24j)NC(O)O—, aryl, Het or R25C(O)— (which aryl and Het are optionally substituted by one or two halogens, C1-C4 alkyl, hydroxy C1-C4alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkoxy, nitro); R6—O—(CH2)m—O—, R7aOC(O)—, (R7b)(R7c)NC(O)—, R7dC(O)N(R7e)—, R7fC(O)O—, R7gC(O)S—, R7hOC(O)N(R7j)—, (R7k)(R71)NC(O)O—, R7mOC(O)O—, R8—SO2—NH—, phtalimido, succinimido, R9C(O)—, R10—(CH2)n—C(O)— or (R11a)(R11b)(R11c)C—C(O)O—;
(B) aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, C1-C7 alkoxy, halogen, R12aOC(O)—, (R12b)(R12c)NC(O)—, R12dC(O)N(R12e)—, R12fC(O)O—, R12gOC(O)NR12h—, (R12j)(R12k)NC(O)O—, aryl, benzoyl or Het4), R13C(O)— or (R14a)(R14b)N—); or R1 and R2 together may represent a cyclic structure containing 5-14 members, optionally substituted by one or more groups selected from hydroxy, oxo, C1-C7 alkyl (which alkyl group is optionally substituted by one or more groups selected from hydroxy, halogen, aryl or Het7), R15O—, R16aOC(O)—, (R16b)(R16c)NC(O)—, R16dC(O)N(R16e)—, R16fC(O)O—, R16gOC(O)NR16h—, (R16j)(R16)NC(O)O—, R17C(O)—, aryl or Het (which aryl or Het5 are optionally substituted by one or more of C1-C7 alkyl, hydroxy, oxo, C1-C7 alkoxy, halogen, R26aOC(O)—, (R26b)(R26c)NC(O)—, R26dC(O)N(R26e)—, R26fC(O)O—, R26gOC(O)NH—, (R26h)(R26j)NC(O)O—, phenyl or benzoyl (which phenyl or benzoyl are optionally substituted by one or two halogens or C1-C5 alkyl C(O)O—)), phtalimido, succinimido or (R18a)(R18b)(R18c)C—C(O)O—;
or R1, R2 and R3 together may represent a cyclic structure containing 5-16 members, optionally substituted by one or more groups selected from hydroxy, oxo, C1-C7 alkyl (which alkyl group is optionally substituted by one or more groups selected from hydroxy, halogen, oxo, aryl or Het8), R19O—, R2OC(O)—, aryl or Het (which aryl or Het are optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, C1-C7 alkoxy, halogen, oxo, R27aOC(O)—, (R27b)(R27c)NC(O)—, R27dC(O)N(R27e)—, R27fC(O)O—, R27gOC(O)—NH—, (R27h)(R27j)NC(O)O—, phenyl or benzoyl), R21aOC(O)—, (R21b)(R21c)NC(O)—, R21dC(O)N(R21e)—, R21fC(O)O—, R21gOC(O)—NR21h—, (R21j)(R21k)NC(O)O—, phtalimido, succinimido or (R22a)(R22b)(R22c) C—C(O)O—;
wherein
R5 is selected from C1-C6 alkyl, aryl, Het9 (which groups are optionally substituted by one or more groups selected from hydroxy, halogen, C1-C6 alkoxy);
R6 is selected from aryl or Het (both groups optionally substituted by one or more groups selected from C1-C8 alkyl, hydroxy, C1-C7 alkoxy, halogen, R28aOC(O)—, (R28b)(R28c)NC(O)—, R28dC(O)N(R28e)—, R28fC(O)O—, R28gOC(O)—NH—, (R28h)(R28j)NC(O)O—, aryl, benzoyl or Het11);
R7a to R7m are independently selected, at each occurrence, from hydrogen, C1-C7 alkyl, aryl or Het12 (which C1-C7 alkyl, aryl and Het12 are optionally substituted by one or more groups selected from C1-C6 alkyl, hydroxy, C1-C3 alkoxy, halogen, R29aOC(O)—, (R29b)(R29c)NC(O)—, R29dC(O)N(R29e)—, R29fC(O)O—, R29gOC(O)—NH—, (R29h)(R29j)NC(O)O—, aryl, benzoyl or Het13);
R8 is selected from C1-C6 alkyl, aryl or Het (which groups are optionally substituted by one or more groups selected from C1-C6 alkyl);
R9 is selected from linear or branched C1-C12 alkyl (optionally substituted by R30OC(O)—), C3-C12 cycloalkyl (which cycloalkyl group is optionally further substituted by one or more groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R31aOC(O)—, (R31b)(R31c)NC(O)—, R31dC(O)NR31e—, R31fC(O)O—, R31g C(O)N(R31h)—, (R31j)(R31k)NC(O)O—), aryl, benzoyl or Het15), aryl or Het16 (which aryl and Het16 are optionally substituted by one to three of the groups selected from C1-C6 alkyl, hydroxy, C1-C3 alkoxy, ethylenedioxy, halogen, R32aOC(O)—, (R32b)(R32c)NC(O)—, R32dC(O)NR32e—, R32fC(O)O—, R32gOC(O)NH—, (R32h)(R32j)NC(O)O—), aryl, benzoyl or Het17);
R10 is selected from aryl and Het18 (which groups are optionally substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, —COOH, ethylenedioxy);
R11a is selected from hydroxy or —CH2OH;
R11b is phenyl (optionally substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R33aOC(O)—, (R33b)(R33c)NC(O)—, R33dC(O)N(R33e)—, R33fC(O)O—, R33gOC(O)—NH—, (R33h)(R33j)NC(O)O—;
R11c is selected from hydrogen, C5-C6 cycloalkyl or phenyl (which groups are optionally substituted by one to three groups selected from C1-C3alkyl, hydroxy, C1-C3alkoxy, halogen, R34aOC(O)—, (R34b)(R34c)NC(O)—, R34dC(O)N(R34e)—, R34fC(O)O—, R34gOC(O)NH—, (R34h)(R34j)NC(O)O—);
R12a to R12k are independently selected, at each occurrence, from hydrogen, C1-C7alkyl, aryl, Het 9 (which groups are optionally substituted by one or more groups selected from C1-C6alkyl, hydroxy, C1-C3alkoxy, halogen, R35aOC(O)—, (R35b)(R35c)NC(O)—, R35dC(O)N(R35e)—, R35fC(O)O—, R35gOC(O)—NH—, (R35h)(R35j)NC(O)O—, aryl, benzoyl or Het20);
R13 is selected from hydrogen or C1-C6 alkyl;
R14a to R14b are independently selected, at each occurrence, from hydrogen or C1-C6 alkyl;
R15 is selected from C1-C6 alkyl, aryl or Het21 (which groups are optionally substituted by one or more groups selected from hydroxy, halogen or C1-C6 alkoxy);
R16a to R16k are independently selected from, at each occurrence, hydrogen, C1-C7 alkyl, aryl or Het22 (which groups are optionally substituted by one or more groups selected from C1-C6 alkyl, hydroxy, C1-C3 alkoxy, halogen, R36aOC(O)—, (R36b)(R36c)NC(O)—, R36dC(O)N(R36e)—, R36fC(O)O—, R36gOC(O)—NH—, (R36h)(R36j)NC(O)O—, aryl, benzoyl or Het23);
R17 is selected from hydrogen or C1-C6 alkyl;
R18a is selected from hydroxy or —CH2OH;
R18b is phenyl (optionally substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R37aOC(O)—, (R37b)(R37c)NC(O)—, R37dC(O)N(R37e)—, R37fC(O)O—, R37gOC(O)—NH—, (R37h)(R37j)NC(O)O—);
R18c is selected from hydrogen, C5-C6 cycloalkyl or phenyl (which groups are optionally substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R38aOC(O)—, (R38b)(R38c)NC(O)—, R38dC(O)N(R38e)—, R38fC(O)O—, R38gOC(O)—NH—, (R38h(R38j)NC(O)O—;
R19 is selected from C1-C6 alkyl, aryl or Het24 (which groups are optionally substituted by one or more groups selected from hydroxy, halogen, C1-C6 alkoxy);
R20 is selected from hydrogen and C1-C6 alkyl;
R21a to R21k are independently selected, at each occurrence, from hydrogen, C1-C7 alkyl, aryl or Het25 (which groups are optionally substituted by one or more groups selected from C1-C6 alkyl, hydroxy, C1-C3 alkoxy, halogen, R39aOC(O)—, (R39b)(R39c)NC(O)—, R39dC(O)N(R39e)—, R39fC(O)O—, R39gOC(O)—NH—, (R39h)(R39j)NC(O)O—, aryl, benzoyl or Het26);
R22a is selected from hydroxy or —CH2OH;
R22b is phenyl (optionally substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R40aOC(O)—, (R40b)(R40c)NC(O)—, R40dC(O)N(R40e)—, R40fC(O)O—, R40gOC(O)NH—, (R40h)(R40j)NC(O)O—);
R22c is selected from hydrogen, C5-C6 cycloalkyl or phenyl (which optionally is substituted by one to three groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, R41aOC(O), (R41b)(R41c)NC(O)—, R41dC(O)N(R41e)—, R41f C(O)O—, R41gOC(O)NH—, (R41h)(R41j)NC(O)O—);
R23a to R23j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R24a to R24j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R25 is selected from C1-C4alkyl, aryl or Het27 (which aryl and Het27 are optionally substituted by one or two halogens, C1-C4 alkyl, hydroxy C1-C4alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkoxy, nitro);
R26a to R26j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R27a to R27j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R28a to R28j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R29a to R29j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R30 is selected from hydrogen or C1-C6 alkyl;
R31a to R31k are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R32a to R32c are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R33a to R33j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R34a to R34j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R35a to R35j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R36a to R36j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R37a to R37j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R38a to R38j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R39a to R39j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R40a to R40j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
R41a to R41j are independently selected, at each occurrence, from hydrogen or C1-C6alkyl;
m is an integer selected from 1 to 5;
n is an integer selected from 1 to 3.
The compound of formula I as defined by formula I is hereby defined as the compound of the invention.
The process for preparing the quaternary ammoniumsalts esomeprazole of formula I comprises the following steps:
(i): mixing esomeprazole and N+(R1)(R2)(R3)(R4) X−;
wherein R1, R2, R3 and R4 are as defined above; X− is selected from Cl−, Br−, I−, carboxylates, sulphonates, HSO4− and OH−; in an aqueous solvent system substantially saturated with potassium carbonate;
(ii): adding a water immiscible chlorinated hydrocarbon solvent;
(iii): isolating the organic phase;
(iv): recovering of the compound of formula I.
In one embodiment of the invention the reaction of the esomeprazole and the N+(R1)(R2)(R3)(R4) X− as defined above is performed in an aqueous solvent substantially saturated with potassium carbonate (K2CO3).
By “substantially saturated” it is meant a solution comprising equal or more than 40% by weight potassium carbonate in an aqueous solvent, for example more than 45, 50 or 55% by weight.
In one embodiment of the invention, the aqueous solvent system in step (i) is saturated with potassium carbonate, i.e. comprises about 56% by weight potassium carbonate.
In one embodiment of the invention the esomeprazole and the quartenary ammoniumsalt of formula N+(R1)(R2)(R3)(R4) X− are in step (i) added in equimolar amounts.
The aqueous solvent system may be selected from water or water soluble solvents, such as alcohols, ethers, amides, nitrites soluble in water; or mixtures thereof. Examples of water soluble solvents are methanol, ethanol, dioxane, tetrahydrofuran, acetonitril and DMF.
In one embodiment the aqueous solvent system is water.
The water immiscible solvent forming the organic phase are selected from solvents such as chlorinated solvents suitable for phase transfer. The solvent must also be stable in the presence of base, i.e. for the present invention the solvent should not degrade more than to some extent in the presence of the potassium carbonate. Examples of chlorinated solvents are dichloromethane, trichloromethane and 1,2-dichloroethane.
In one embodiment the compound of the invention is a quartenary alkyl ammoniumsalt of esomeprazole of formula I wherein R1 is selected from
(A) C1-C14 alkyl group, which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O—, C3-C12 cycloalkyl (which cycloalkyl is optionally substituted by one or more groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, oxo, R23aOC(O)—, (R23b)(R23c)NC(O)—, R23dC(O)N(R23e)—, R23fC(O)O—, R23gOC(O)—NH— or (R23h)(R23j)NC(O)O—), aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, —CH2OH, halogen, oxo, nitro, C1-C7 alkoxy, R24aOC(O)—, (R24b)(R24c)NC(O)—, R24dC(O)N(R24e)—, R24fC(O)O—, R24gOC(O)—NH—, (R24h)(R24j)NC(O)O—, aryl, Het3 or R25C(O)— (which aryl and Het3 are optionally substituted by one or two halogens, C1-C4 alkyl, hydroxy C1-C4alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkoxy, nitro); R6—O—(CH2)m—O—, R7aOC(O)—, (R7b)(R7c)NC(O)—, R7dC(O)N(R7e)—, R7fC(O)O—, R7gC(O)S—, R7hOC(O)N(R7j)—, (R7k)(R71)NC(O)O—, R7mOC(O)O—, R8—SO2—NH—, phtalimido, succinimido, R9C(O)—, R10—(CH2)n—C(O)— or (R11a)(R11b)(R11c)C—C(O)O—;
(B) aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, C1-C7 alkoxy, halogen, R12aOC(O)—, (R12b)(R12c)NC(O)—, R12dC(O)N(R12e)—, R12fC(O)O—, R12gOC(O)NR12h—, (R12j)(R12k)NC(O)O—, aryl, benzoyl or Het4), R13C(O)— or (R14a)(R14b)N—);
R2, R3 and R4 are individually selected from linear or branched C1-C14alkyl group (which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, phenyl and R5O—) or aryl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1, R2 and R3 are individually selected from
(A) C1-C14 alkyl group, which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O—, C3-C12 cycloalkyl (which cycloalkyl is optionally substituted by one or more groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, oxo, R23aOC(O)—, (R23b)(R23c)NC(O)—, R23dC(O)N(R23e)—, R23fC(O)O—, R23gOC(O)—NH—, (R23h)(R23j)NC(O)O—), aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, —CH2OH, halogen, oxo, nitro, C1-C7 alkoxy, R24aOC(O)—, (R24b)(R24c)NC(O)—, R24dC(O)N(R24e)—, R24fC(O)O—, R24gOC(O)—NH—, (R24h)(R24j)NC(O)O—, aryl, Het or R25C(O)— (which aryl and Het3 are optionally substituted by one or two halogens, C1-C4 alkyl, hydroxy C1-C4alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkoxy, nitro); R6—O—(CH2)m—O—, R7aOC(O)—, (R7b)(R7c)NC(O)—, R7dC(O)N(R7e)—, R7fC(O)O—, R7gC(O)S—, R7hOC(O)N(R7j)—, (R7k)(R7l)NC(O)O—, R7mOC(O)O—, R8—SO2—NH—, phtalimido, succinimido, R9C(O)—, R10-(CH2)n—C(O)— or (R11a)(R11b)(R11c)C—C(O)O—;
(B) aryl or Het2 (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, C1-C7 alkoxy, halogen, R12aOC(O)—, (R12b)(R12c)NC(O)—, R12dC(O)N(R12e)—, R12fC(O)O—, R12gOC(O)NR12h—, (R12j)(R12k)NC(O)O—, aryl, benzoyl or Het4), R13C(O)— or (R14a)(R14b)N—); and R4 is selected from linear or branched C1-C6alkyl group.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1, R2 and R3 are defined as above and R4 is methyl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 and R2 are individually selected from
(A) C1-C14 alkyl group, which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O—, C3-C12 cycloalkyl (which cycloalkyl is optionally substituted by one or more groups selected from C1-C3 alkyl, hydroxy, C1-C3 alkoxy, halogen, oxo, R23aOC(O)—, (R23b)(R23c)NC(O)—, R23dC(O)N(R23e)—, R23fC(O)O—, R23gOC(O)—NH—, (R23h)(R23j)NC(O)O—), aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, —CH2OH, halogen, oxo, nitro, C1-C7 alkoxy, R24aOC(O)—, (R24b)(R24c)NC(O)—, R24dC(O)N(R24e)—, R24fC(O)O—, R24gOC(O)—NH—, (R24h)(R24j)NC(O)O—, aryl, Het or R25C(O)— (which aryl and Het are optionally substituted by one or two halogens, C1-C4 alkyl, hydroxy C1-C4alkyl, C1-C4 alkoxy, hydroxy C1-C4 alkoxy, nitro); R6—O—(CH2)n—O—, R7aOC(O)—, (R7b)(R7c)NC(O)—, R7dC(O)N(R7e)—, R7fC(O)O—, R7gC(O)S—, R7hOC(O)N(R7j)—, (R7k)(R71)NC(O)O—, R7mOC(O)O—, R8—SO2—NH—, phtalimido, succinimido, R9C(O)—, R10—(CH2)n—C(O)— or (R11a)(R11b)(R11c)C—C(O)O—;
(B) aryl or Het (both groups optionally substituted by one to three groups selected from C1-C7 alkyl, hydroxy, C1-C7 alkoxy, halogen, R12aOC(O)—, (R12b)(R12c)NC(O)—, R12dC(O)N(R12e)—, R12fC(O)O—, R12gOC(O)NR12h—, (R12j)(R12k)NC(O)O—, aryl, benzoyl or Het4), R13C(O)— or (R14a)(R14b)N—); and R3 and R4 are individually selected from, at each occurrence, linear or branched C1-C6alkyl group.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 and R2 are defined as above; and R3 and R4 are methyl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is as defined above, R2, R3 and R4 are individually selected from, at each occurrence, linear or branched C1-C6alkyl group.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is as defined above, R2 and R3 are individually selected from, at each occurrence, linear or branched C1-C6alkyl group; and R4 is methyl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is as defined above, R2 is selected from linear or branched C1-C6alkyl group; and R3 and R4 are methyl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is as defined above, R2, R3 and R4 are methyl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is as defined above, R2, R3 and R4 are individually selected from C1-C4-alkyl groups.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 and R2 together may represent a cyclic structure containing 5 to 10 members, optionally substituted by on or more groups selected linear or branched C1-C5 alkyl group, amino, hydroxy, halogen or R5O—; R3 and R4 are selected from linear or branched C1-C4 alkyl group.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is selected from linear or branched C1-C8 alkyl group (which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O— or aryl). R2, R3 and R4 are individually selected from linear or branched C1-C4alkyl group (which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen or R5O—) or aryl.
In one embodiment of the invention the compound of the invention is according to formula I wherein R1 is selected from linear or branched C1-C8 alkyl group (which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen, R5O— or phenyl). R2, R3 and R4 are individually selected from linear or branched C1-C4alkyl group (which alkyl group is optionally substituted by one or more groups selected from amino, hydroxy, halogen or R5O—) or phenyl.
In one embodiment R1 is selected from linear or branched C1-C8 alkyl group, which alkyl group is optionally substituted by one or more groups selected from phenyl, amino, hydroxy, halogen or R5O—. R2, R3 and R4 are selected from linear or branched C1-C4 alkyl group, for example, methyl, ethyl, n-propyl or isopropyl.
In one embodiment R1 and R2 together may represent a cyclic structure containing 5 to 10 members, optionally substituted by on or more groups selected linear or branched C1-C5 alkyl group, amino, hydroxy, halogen or R5O—. R3 and R4 are selected from linear or branched C1-C4 alkyl group, for example, methyl, ethyl, n-propyl or isopropyl.
In one embodiment R1, R2, R3 and R4 are as defined above, provided that R1, R2, R3 and R4 are not simultaneously C1 alkyl group (methyl).
In one embodiment of the invention the compound of the invention is quaternary alkyl ammoniumsalt of S-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole (esomeprazole) of formula I
wherein
R1, R2, R3 and R4 are as defined in any place in this application, obtainable by the process described above.
Unless otherwise specified, alkyl groups and alkoxy groups as defined herein may be linear or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms be branched, and/or cyclic.
As used herein, the term “C1-C14 alkyl group” is an alkyl group having 1 to 14 carbon atoms. Examples of said group includes, but is not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl and dekanyl and when the alkyl is branched, iso-propyl, iso-butyl, sec-butyl, tert-butyl, sec-pentyl, iso-pentyl and neo-pentyl.
The term “C3-C12 cycloalkyl” is a cyclic alkyl group having 3 to 12 carbon atoms. The cyclic group may be a mono, di or polycyclic-group, and it may optionally be substituted with 1, 2, or 3 methyl groups. Examples of said cyclic alkyl group includes, but is not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and adamantyl.
Unless otherwise specified, the alkyl and alkoxy groups may also be substituted by one or more fluoro atoms. Examples of said substituted alkyl or alkoxy groups are trifluoromethyl, trifluoromethoxy and trifluoroethyl.
Alkylene groups as defined herein are divalent and may be linear or, when there is a sufficient number (i.e. a minimum of three) of carbon atoms, be branched. Unless otherwise specified, alkylene groups may also be substituted by one or more halogen atoms, and especially fluoro atoms.
The term “aryl”, when used herein, includes C6-C10 aryl groups such as phenyl, naphtyl, and the like. Unless otherwise specified, the aryl group may be substituted by one or more substituents including —OH, cyano, nitro, C1-C7 alkoxy, C1-C7 alkyl, halogen for example fluoro. Examples are phenyl substituted by one, two or three halogens such as fluoro. Unless otherwise specified the term “benzoyl” also includes benzoyl groups which may be substituted by one or more halogen, for example fluoro.
Het groups (Het1 to Het27) that may be mentioned include those ring systems having a total number of atoms in the ring system or between five and twelve atoms and containing 1 to 5 heteroatoms (selected from N, O and S). Het groups may be fully saturated, wholly aromatic, partly aromatic and/or bi- or polycyclic in character. Heterocyclic groups that may be mentioned include benzodioxanyl, benzodioxepanyl, benzodioxolyl, benzofuranyl, benzimidazolyl, benzomorpholinyl, benzoxazinonyl, benzothiophenyl, chromanyl, cinnolinyl, dioxanyl, furanyl, imidazolyl, imidazo[1,2-a]pyridinyl, indolyl, isoquinolinyl, isoxazolyl, morpholinyl, oxazolyl, phthalazinyl, piperazinyl, piperidinyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl, pyrimindinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, pyrrolyl, quinazolinyl, quinolinyl, tetrahydropyranyl, tetrahydrofuranyl, thiazolyl, thienyl, thiochromanyl, triazolyl, xanthanyl and the like. Substituents on Het groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of Het groups may be via any atom in the ring system including (where appropriate) a heteroatom, or an atom on any fused carbocyclic ring that may be present as part of the ring system. Het groups may also be in the N- or S-oxidised form. Unless otherwise specified, the Het group may be substituted by one or more substituents including —OH, cyano, nitro, C1-C7 alkoxy, C1-C7 alkyl, halogen for example fluoro.
The term “halogen”, when used herein, includes fluoro, chloro, bromo and iodo.
The phrase “R1 and R2 together may represent a cyclic structure containing 5-14 members” means that a mono-, bi-, tri- or polycyclic structure containing 5-14 atoms, of which optionally 1 to 5 are heteroatoms selected from N, O and S is formed. The cyclic structure may contain one or more double bond, and which cyclic structure may have one or more condensed aryl or Het. The cyclic structure may be further substituted. Examples of compounds included are pyrrolidine, piperidine, azepane, piperidone, piperazine, morpholine, tetrahydropyridine, imidazole, imidazoline, isoindoline, tetrahydroisoquinoline, carbazole, 6,7-dihydro-5H-dibenzo[c,e]azepine, 8-aza-bicyclo[3,2,1]octane, desmethyltropine, 3-oxa-9-aza-tricyclo[3.3.1.0*2,4*]nonane and desmethylscopine.
The phrase “R1, R2 and R3 together may represent a cyclic structure containing 5-16 members” means that R1, R2 and R3 together form a tri-, tetra- or polycyclic structure containing 5 to 16 atoms, of which optionally 1 to 5 are heteroatoms selected from N, O and S. The cyclic structure may contain one or more double bond, and which cyclic structure may have a condensed aryl or Het and which cyclic structure may optionally be further substituted by one or more groups. Examples of structures included are hexamethylenetetramine and quinuclidine.
The N(R1)(R2)(R3)(R4) X added in step (i) is defined to be salts of Cl−, Br−, I−, carboxylates, sulphonates, HSO4− and OH−. Examples of carboxylates are aliphatic carboxylic acids, for example C1-C6 alkyl carboxylic acid, such as acetic acid and propionic acid; of sulphonates are alkylsulphonates, for example C1-C6 alkyl sulphonates such as methane-, ethane- or propanesulphonic acid.
In one embodiment of the invention, the compound of the invention provided by the process above is
tetra-n-butyl ammoniumsalt of esomeprazole;
cholin salt of esomeprazole;
benzyltrimethylammonium salt of esomeprazole;
Due to tautomerism the chemical name (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole ammonium salt does not necessarily mean that the methoxy group of the two benzimidazole moieties is in the 5-position but may as well be in the 6-position, or there may be mixtures of the two.
The compounds of the invention may be prepared in the form of solvates, hydrates, and anhydrates.
The esomeprazole mixed in step (i) of the process of the invention is the neutral form esomeprazole, or the sodium salt or potassium salt of esomeprazole.
The process of the present invention is advantageous because of its simplicity. The process of the present of invention is defined by increased ease of handling including improved phase separation in step (iii) and an inherent drying off effect. During a phase transfer, most often a small amount of water remains in the organic phase. However, the presence of potassium carbonate in the present process reduces or even eliminates the remaining parts of aqueous solvent system in the organic phase, and thus also the need for a following drying step. It further gives products of high purity.
The compounds of the present invention are effective as gastric acid secretion inhibitors, and are thus useful as antiulcer agents. In a more general sense, they can be used for prevention and treatment of gastric-acid related conditions in mammals and especially in man, including e.g. reflux esophagitis, gastritis, duodenitis, gastric ulcer and duodenal ulcer. Furthermore, they may be used for treatment of other gastrointestinal disorders where gastric acid inhibitory effect is desirable e.g. in patients on NSAID therapy, in patients with Non Ulcer Dyspepsia, in patients with symptomatic gastro-esophageal reflux disease, and in patients with gastrinomas. They may also be used in patients in intensive care situations, in patients with acute upper gastrointestinal bleeding, pre- and postoperatively to prevent aspiration of gastric acid, to prevent and treat stress ulceration and asthma, and for improvement of sleep. Further, the compounds of the invention may be useful in the treatment of psoriasis as well as in the treatment of Helicobacter infections and related diseases. The compounds of the invention may also be used for treatment of inflammatory conditions in mammals, including man.
Any suitable route of administration may be employed for providing the patient with an effective dosage of the quartenary ammoniumsalt of esomeprazole. For example, peroral or parenteral formulations, including i.v., and the like may be employed. Dosage forms include capsules, tablets, dispersions, suspensions, solutions and the like.
It is further provided a pharmaceutical composition comprising the compounds of the present invention, as active ingredient, in association with a pharmaceutically acceptable carrier, diluent or excipient and optionally other active pharmaceutical ingredients. Compositions comprising other therapeutic ingredients are of interest in the treatment of the conditions listed above. The invention also provides the use of the compounds of the invention in the manufacture of a medicament for use in said conditions as well as a method of treating a gastric-acid related condition which method comprises administering to a subject suffering from said condition a pharmaceutically effective amount of the compounds of the invention.
The compositions of the invention include compositions suitable for peroral or parenteral administration. The compositions may be conveniently presented in unit dosage forms, and prepared by any methods known in the art of galenic pharmacy.
In the practice of the invention, the most suitable route of administration as well as the magnitude of the therapeutic dose will depend on the nature and severity of the disease to be treated. The dose, and dose frequency, may also vary according to the age, body weight and response of the individual patient. Special requirements may be needed for patients having Zollinger-Ellison syndrome, such as a need for higher doses than the average patient. Children and patients with liver diseases generally will benefit from doses that are somewhat lower than average. Thus, in some conditions it may be necessary to use doses outside the ranges stated below, for example long-term treatments may request lower dosage. Such higher and lower doses are within the scope of the present invention. Such daily doses may vary between 5 mg to 300 mg.
In general, a suitable oral dosage form of the compound of the invention may cover a dose range from 5 mg to 300 mg total daily dose, administered in one single dose or equally divided doses. A preferred dosage range is from 10 mg to 80 mg.
The compound of the invention may be combined as the active component in intimate admixture with a pharmaceutical carrier according to conventional techniques, such as the oral formulations described in WO 96/01623 and EP 0 247 983, the disclosures of which are hereby as a whole included by reference.
Combination preparations comprising the compounds of the invention and other active ingredients may also be used. Examples of such active ingredients include, but are not limited to anti-bacterial compounds, non-steroidal anti-inflammatory agents, antacid agents, alginates and prokinetic agents.
The compounds of the invention may be further processed before formulation into a suitable pharmaceutical formulation.
For the avoidance of doubt, “treatment” includes the therapeutic treatment, as well as the prophylaxis, of a condition.
The examples below will further illustrate the preparation of the compound of the invention. These examples are not intended to limit the scope if the invention as defined hereinabove or as claimed below.
The quaternary ammoniumsalt of formula N(R1)(R2)(R3)(R4)Cl− as defined above may be commercially available or otherwise synthesized according to the methods described below in Example A to Example F.
(1S)—N,N-dimethyl-1-phenetylamine (0.61 g, (4 mmol)) was dissolved in acetone (20 ml) and methyl iodide (2 g (14 mmol)) was added. The flask was sealed and the mixture was left over night at ambient temperature before it was diluted with diethyl ether (50 ml). The crystalline salt was filtered off and washed with diethyl ether. The quarternary ammonium iodide was dissolved in water (deionised) and the solution was filtered through an anion exchanger (50 ml Amberlite IRA-400; 20-50 mesh; Cl− form) and eluted with deionized water. The eluate was concentrated to ca 20 ml at reduced pressure and freeze drying gave is 600 mg (3 mmol) of crystalline (1S)—N,N,N-trimethyl-1-phenetylammonium chloride.
1H-NMR (400 MHz; CDCl3): δ 7.59 (m, 1H), 7.43 (m, 3H), 5.33 (q, 2H), 3.34 (s, 9H), 1.81 (δ, 3H).
(1R,2S)—N-methylephedrin (0.72 g, (4 mmol)) was dissolved in acetone (20 ml) and methyl iodide (2 g (14 mmol)) was added. The flask was sealed and the mixture was left over night at ambient temperature before it was diluted with diethyl ether (50 ml). The crystalline salt was filtered off and washed with diethyl ether. The quarternary ammonium iodide was dissolved in water (deionised) and the solution was filtered through an anion exchanger (50 ml Amberlite IRA-400; 20-50 mesh; Cl− form) and eluted with deionized water. The eluate was concentrated to ca 20 ml at reduced pressure and freeze drying gave 685 mg (3 mmol) of crystalline (1R,2S)—N,N-dimethylephedrinium chloride.
1H-NMR (400 MHz; CDCl3): δ 7.27 (m, 2H), 7.22 (m, 2H), 5.42 (s, 1H), 3.46 (m, 1H), 3.19 (m, 1H), 3.16 (s, 9H), 1.08 (m, 3H).
(1S,2R)—N-methylephedrin (0.72 g, (4 mmol)) was dissolved in acetone (20 ml) and methyl iodide (2 g (14 mmol)) was added. The flask was sealed and the mixture was left over night at ambient temperature before it was diluted with diethyl ether (50 ml). The crystalline salt was filtered off and washed with diethyl ether. The quarternary ammonium iodide was dissolved in water (deionised) and the solution was filtered through an anion exchanger (50 ml Amberlite IRA-400; 20-50 mesh; Cl−-form) and eluted with deionized water. The eluate was concentrated to ca 20 ml at reduced pressure and freeze drying gave 850 mg (3.7 mmol) of crystalline (1S,2R)—N,N-dimethylephedrinium chloride.
1H-NMR (400 MHz; CDCl3): δ 7.27 (m, 2H), 7.22 (m, 2H), 5.42 (s, 1H), 3.46 (m, 1H), 3.19 (m, 1H), 3.16 (s, 9H), 1.08 (m, 3H).
(1R,2S)—N-methylephedrin (0.5 g, (2.79 mmol)) was dissolved in dimethoxyethane (5 ml) and benzyl bromide (0.6 g (3.5 mmol)) was added. The flask was sealed and the mixture was left over night at ambient temperature before it was diluted with diethyl ether (10 ml). The crystalline salt was filtered off and washed with diethyl ether. Air drying at room temperature gave 0.74 g (2.11 mmol) of the title compound.
1H-NMR (400 MHz; CDCl3): δ 7.60 (d, 2H), 7.40 (bm, 5H), 7.19 (m, 2H), 7.12 (m, 1H), 5.95 (d, 1H), 5.37 (d, 1H), 5.20 (d, 1H), 4.91 (d, 1H), 3.98 (q, 1H), 3.30 (s, 3H), 3.19 (s, 3H), 1.24 (d, 3H).
(1S,2R)—N-methylephedrin (0.5 g, (2.79 mmol)) was dissolved in dimethoxyethane (5 ml) and benzyl bromide (0.6 g (3.5 mmol)) was added. The flask was sealed and the mixture was left over night at ambient temperature before it was diluted with diethyl ether (10 ml). The crystalline salt was filtered off and washed with diethyl ether. Air drying at room temperature gave 0.75 g (2.14 mmol) of the title compound.
1H-NMR (400 MHz; CDCl3): δ 7.60 (d, 2H), 7.40 (bm, 5H), 7.19 (m, 2H), 7.12 (m, 1H), 5.95 (d, 1H), 5.37 (d, 1H), 5.20 (d, 1H), 4.91 (d, 1H), 3.98 (q, 1H), 3.30 (s, 3H), 3.19 (s, 3H), 1.24 (d, 3H).
Methyl iodide (2 g (14 mmol)) was added to a mixture of cis-2,6-dimethylpiperidine (0.46 g (4 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml) in dichloromethane (8 ml). The mixture was shaken carefully for 10 min whereupon the phases were separated. The organic phase was concentrated to drieness at reduced pressure and the crystalline residue was treated with acetone. Filtration and air drying gave 0.92 g (3.42 mmol) of the title compound.
1H-NMR (400 MHz; CDCl3): δ 4.20 (m, 2H), 3.35 (s, 3H), 2.86 (s, 3H), 1.86 (m, 6H), 1.47 (d, 6H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of tetra-n-butylammonium chloride (0.28 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken by hand (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.58 g (0.98 mmol) of tetra-n-butylammonium salt of esomeprazole (oil) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.21 (s, 1H), 7.54 (d, 1H), 7.18 (m, 1H), 6.74 (dm, 1H), 4.94 (d, 1H), 4.65 (D, 1H), 3.82 (s, 3H), 3.63 (s, 3H), 2.97 (bm, 8H), 2.19 (s, 3H), 2.18 (s, 3H), 1.29 (bm, 16H), 0.93 (bt, 12H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of cholin chloride (0.14 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.44 g (0.98 mmol) cholin salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.14 (s, 1H), 7.50 (d, 1H), 7.10 (m, 1H), 6.79 (dm, 1H), 4.83 (d, 1H), 4.57 (d, 1H), 3.84 (m, 2H), 3.82 (s, 3H), 3.67 (s, 3H), 3.27 (m, 1H), 3.10 (m, 1H), 2.93 (s, 9H), 2.20 (s, 3H), 2.19 (s, 3H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of benzyl trimethyl ammonium chloride (0.19 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.48 g (0.97 mmol) of benzyltrimethylammonium salt of esomeprazole (oil) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.12 (s, 1H), 7.52 (d, 1H), 7.38 (bm, 3H), 7.21 (bd, 2H), 7.14 (m, 1H), 6.74 (dm, 1H), 4.91 (d, 1H), 4.62 (d, 1H), 4.13 (s, 2H), 3.76 (s, 3H), 3.65 (s, 3H), 2.74 (s, 9H), 2.20 (s, 3H), 2.15 (s, 3H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of (1S)—N,N,N, trimethyl-1-phenylethylammonium chloride (0.2 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.50 g (0.98 mmol) of (1S)—N,N,N, trimethyl-1-phenylethylammonium salt of esomeprazole (oil) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.15 (s, 1H), 7.54 (d, 1H), 7.35 (bm, 5H), 7.15 (m, 1H), 6.77 (dm, 1H), 4.92 (d, 1H), 4.66 (d, 1H), 3.78 (s, 3H), 4.57 (q, 1H) 3.65 (s, 3H), 2.84 (s, 9H), 2.20 (s, 3H), 2.17 (s, 3H), 1.54 (d, 3H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of (1R,2S)—N,N-dimethylephedrinium chloride (0.23 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.505 g (0.98 mmol) of (1R, 2S)—N,N-dimethylephedrinium salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.06 (s, 1H), 7.38 (bm, 3H), 7.26 (bm, 2H), 7.19 (m, 1H), 6.88 (m, 1H), 6.68 (dm, 1H), 5.83 (s, 1H), 4.65 (d, 1H), 4.42 (d, 1H), 3.65 (s, 3H), 3.56 (s, 3H), 3.10 (q, 1H), 2.86 (s, 9H), 2.14 (s, 3H), 1.93 (s, 3H), 1.10 (d, 3H).
Esomeprazole sodium salt (0.37 g (1 mmol)) was added to a mixture of (1S,2R)—N,N-dimethylephedrinium chloride (0.23 g (1 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.53 g (0.98 mmol) of (1S, 2R)—N,N-dimethylephedrinium salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.09 (s, 1H), 7.35 (bm, 3H), 7.28 (bm, 2H), 7.22 (m, 1H), 6.79 (m, 1H), 6.66 (dm, 1H), 5.60 (s, 1H), 4.76 (d, 1H), 4.52 (d, 1H), 3.62 (s, 3H), 3.57 (s, 3H), 3.13 (q, 1H), 2.96 (s, 9H), 2.17 (s, 3H), 2.09 (s, 3H), 1.12 (d, 3H).
Esomeprazole sodium salt (0.185 g (0.5 mmol)) was added to a mixture of (1R,2S)—N-benzyl-N-methylephedrinium bromide (0.175 g (0.5 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.265 g (0.43 mmol) of (1R,2S)—N-benzyl-N-methylephedrinium salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.00 (s, 1H), 7.49 (d, 1H), 7.44 (d, 2H), 7.39 (t, 1H), 7.27 (bm, 3H), 7.13 (d, 2H), 6.99 (d, 1H), 6.70 (dd, 1H), 6.2 (s, 1H), 4.64 (d, 1H), 4.52 (s, 2H), 4.49 (d, 1H), 3.71 (s, 3H), 3.57 (s, 3H), 3.49 (q, 1H), 2.92 (s, 3H), 2.92 (s, 3H), 2.12 (s, 3H), 1.97 (s, 3H), 1.34 (d, 3H).
Esomeprazole sodium salt (0.185 g (0.5 mmol)) was added to a mixture of (1S,2R)—N-benzyl-N-methylephedrinium bromide (0.175 g (0.5 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.260 g (0.42 mmol) of (1S,2R)—N-benzyl-N-methylephedrinium salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 8.01 (s, 1H), 7.40 (m, 3H), 7.37 (d, 1H), 7.27 (bm, 3H), 7.18 (d, 2H), 6.86 (d, 1H), 6.66 (dd, 1H), 5.83 (s, 1H), 4.79 (d, 1H), 4.54 (d, 1H), 4.51 (d, 1H), 4.39 (d, 1H), 3.62 (s, 6H), 3.45 (q, 1H), 2.95 (s, 3H), 2.92 (s, 3H), 2.14 (s, 3H), 2.11 (s, 3H), 1.29 (d, 3H).
Esomeprazole sodium salt (0.368 g (1 mmol)) was added to a mixture of cis-2,6-dimethyl-N,N-dimethylpiperidinium iodide (0.270 g (0.5 mmol)), potassium carbonate (anhydrous) (1 g (7.3 mmol)) and water (1 ml). Dichloromethane (8 ml) was added and the mixture was shaken (1 min). After separation, the organic phase was dried over Na2SO4 and filtered. The filtrate was concentrated to drieness at reduced pressure. 0.470 g (0.96 mmol) cis-2,6-dimethyl-N,N-dimethylpiperidinium salt of esomeprazole (amorphous foam) was obtained.
1H-NMR (400 MHz; CDCl3): δ 7.90 (s, 1H), 7.43 (d, 1H), 7.04 (d, 1H), 6.66 (dd, 1H), 4.61 (d, 1H), 4.44 (d, 1H), 3.68 (s, 3H), 3.62 (s, 3H), 3.41 (bm, 2H), 2.84 (s, 3H), 2.41 (s, 3H), 2.13 (s, 3H), 2.00 (s, 3H), 1.58 (m, 4H), 1.48 (m, 2H), 1.15 (dd, 6H).
| Filing Document | Filing Date | Country | Kind | 371c Date |
|---|---|---|---|---|
| PCT/SE2007/000548 | 6/7/2007 | WO | 00 | 12/3/2008 |
| Number | Date | Country | |
|---|---|---|---|
| 60811698 | Jun 2006 | US |
